$5,343.84 consulting Payment -- Takeda Pharmaceuticals to Dr. Charles Baker

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Takeda Pharmaceuticals made a $5.3K consulting payment to Charles Baker, a Hematology specialist in Toledo, OH. The payment was associated with Eylea. The payment of $5,343.84 to Dr. Charles Baker in Hematology from Takeda Pharmaceuticals for consulting services related to Eylea is a notable transaction. This payment was made on November 17, 2024, indicating a recent engagement between the physician and the pharmaceutical company. The specific nature of the consulting fee suggests an exchange of expertise or advice, potentially related to Takeda's products or research.

Patient Guidance: What This Payment Means for You

This information details a payment made to a healthcare provider for professional services. It is important to understand that such payments are often for legitimate consulting or advisory roles that can help advance medical knowledge and patient care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees for physicians in Hematology can vary widely, but this amount is within a typical range for expert advisory services provided to pharmaceutical companies.

Regulatory Context: Sunshine Act Requirements

Payments made by pharmaceutical companies to physicians are subject to disclosure under the Sunshine Act (part of the Affordable Care Act), requiring transparency in financial relationships.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharmaceutical-payments
• consulting-fees
• physician-compensation
• takeda-pharmaceuticals
• hematology
• eylea

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $5.3K payment for?

This was a consulting payment of $5.3K from Takeda Pharmaceuticals to Charles Baker, categorized as "Consulting Fee". It was associated with Eylea. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Charles Baker accept pharmaceutical money?

Yes, Charles Baker received this $5.3K payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Charles Baker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $5.3K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Hematology?

To compare this payment against Hematology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hematology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Charles Baker's relationship with Takeda Pharmaceuticals?

The payment amount falls within a moderate range for consulting fees in the pharmaceutical industry. This $5.3K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Hematology?

The specialty of Hematology is relevant, as Takeda Pharmaceuticals has products that may be used in this field.

What should patients do after learning about this payment?

This information details a payment made to a healthcare provider for professional services. It is important to understand that such payments are often for legitimate consulting or advisory roles that can help advance medical knowledge and patient care.

What else should I know about this consulting payment?

The drug Eylea, while listed, is manufactured by Regeneron, suggesting the consulting may be broader than a single drug.

Related Reports

• View Dr. Charles Baker's full payment report
• Takeda Pharmaceuticals full spending report
• Browse all Hematology payments
• Browse all payments in Ohio
• Search for other payments